Stille (STIL) Company presentation summary

Company overview and market positioning

• Over 180 years of expertise in premium surgical instruments and advanced surgical tables, serving cardiovascular, cardiac, plastic, spine, neuro, and microsurgical disciplines.

• Product portfolio includes Stille, S & T, Fehling, imagiQ, Medstone, and GS2, with subsidiaries in the US, Germany, Switzerland, Malaysia, and UAE.

• Strong global distribution network and partnerships with leading healthcare companies.

• Publicly traded with a long-term institutional shareholder base and a market cap of SEK 1,950m as of June 2024.

• Trusted by generations of surgeons for quality and innovation.

Product portfolio and innovation

• Offers over 1,000 unique hand-crafted surgical instruments and advanced C-arm tables for minimally invasive procedures.

• Focus on premium, durable instruments for niche specialties, including microsurgery and minimally invasive cardiac surgery.

• C-arm tables feature True Free Float® technology and carbon fiber tops for superior imaging and efficiency.

• Continuous R&D investment and collaborations with leading C-arm providers like GE and Ziehm.

• Manufacturing supported by ISO 13485:2016 and FDA QSR 820 certifications.

Strategic growth and acquisitions

• Growth driven by product leadership, market expansion, operational excellence, and strategic acquisitions.

• Successful acquisition of S & T AG in 2021 doubled the size of the surgical instruments business unit.

• Recent acquisition of Fehling Instruments further expanded the portfolio and market reach.

• Well-positioned to capitalize on market consolidation and transition from distributor to direct sales to capture higher margins.